Amneal Pharmaceuticals, Inc. AMRX Specialty — Restructuring and other charges
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCharges.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — restructuring and other charges.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s specialty — restructuring and other charges?
- Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — restructuring and other charges of $347K in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s specialty — restructuring and other charges changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s specialty — restructuring and other charges increased by 166.9% year-over-year, from $130K to $347K.
- What does specialty — restructuring and other charges mean?
- Costs associated with organizational realignments, facility consolidations, or workforce reductions within the specialty segment intended to improve long-term operational efficiency. These charges are typically excluded from core operating performance to highlight underlying business trends.